Pediatr Allergy Immunol
Allergy Unit, Department of Pediatrics, Meyer Children's University Hospital, Florence, Italy.
Published: January 2022
The diagnosis of drug-induced enterocolitis syndrome (DIES), resembling the typical findings of a well-known disease, the food protein-induced enterocolitis syndrome (FPIES), was acknowledged in the first publication on the topic in 2014. Ten cases of DIES have been described so far. Unanswered questions concerning DIES include its pathogenetic mechanism, natural history, the possible presence of predisposing genetic factors, and the potential existence of its atypical forms. DIES is a recently defined and intriguing clinical entity, similar to FPIES but triggered by drugs. It seems well-defined from the clinical point of view, but its pathogenetic mechanisms are not known. DIES deserves more attention among allergists, especially among the professionals who work with children, and all efforts should be conceived to improve its correct recognition and accurate management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pai.13630 | DOI Listing |
Allergol Immunopathol (Madr)
January 2025
Pediatric Allergy and Pulmonology Unit, Children's University Hospital Reina Sofia, Cordoba, Spain;
Drug-induced enterocolitis syndrome (DIES), little known due to its recent description, is analogous to food protein-induced enterocolitis syndrome (FPIES). Both processes are more frequent in pediatric age and share diagnostic criteria, the main one being the appearance of persistent vomiting 1-4 hours after ingestion of the drug or food, in the absence of IgE-mediated allergy symptoms.
View Article and Find Full Text PDFNutrients
December 2024
Department of Molecular Biology and Genetics, Çanakkale Onsekiz Mart University, Çanakkale 17000, Türkiye.
Bovine colostrum (BC), the first milk secreted by mammals after birth, is a trending alternative source for supplementing infants and children, offering benefits for gut and immune health. Its rich components, such as proteins, immunoglobulins, lactoferrin, and glycans, are used to fortify diets and support development. Preterm development is crucial, especially in the maturation of essential systems, and from 2010 to 2020, approximately 15% of all premature births occurred at less than 32 weeks of gestation worldwide.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
December 2024
Section of Inflammation, Repair and Development, National Heart and Lung Institute. Imperial College London, London, UK. Electronic address:
Background: Oral Food Challenges (OFC) are essential for the diagnosis and follow-up of acute Food Protein-Induced Enterocolitis Syndrome (FPIES) because no diagnostic or prognostic biomarkers are available. However, the optimal OFC procedure remains unclear.
Objectives: This systematic review aimed to assess OFC procedures' design and clinical outcomes in patients with FPIES.
Nutrition
November 2024
UGC Pediatrics, Hospital de la Axarquía, Vélez-Málaga, Málaga, Spain.
Among the possible adverse reactions to gluten, celiac disease, non-celiac gluten sensitivity, and IgE-mediated wheat allergy have been classically described. A non-IgE-mediated reaction similar to food protein-induced enterocolitis syndrome (FPIES) after inadvertent gluten ingestion in a celiac patient was recently reported. We present three children affected by celiac disease with exquisite control, including appropriate adherence to an exclusion diet, who suffered a severe adverse food reaction after unappreciated outdoor ingestion of gluten, meeting the criteria for a definitive diagnosis of FPIES.
View Article and Find Full Text PDFIntroduction Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality among preterm infants, necessitating effective treatment strategies. This study compared the efficacy of Beractant (SURVANTA®) to Poractant alfa (CUROSURF®) in treating RDS in preterm infants admitted to Tawam Hospital in the UAE. Methodology This retrospective study included preterm infants from 23+0 to 36+6 weeks of gestation with a diagnosis of RDS and treatment by Beractant or Poractant alfa within 48 hours of life between January 2020 and March 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.